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7INTRODUCTION
Adaptive immunity 
The following text deals with components of the adaptive immune system, which, in 
contrast to the innate immune system, depends on the generation of a diversity of specific 
receptors and highly selective activation of cells in order to defend the body against 
infectious diseases and cancer. Since adaptive immunity is a result of the activation of 
few antigen-specific progenitor cells, which need to undergo extensive proliferation in 
order to exert their effector function, the response is relatively slow. The innate immune 
system, on the other hand, is always ready to act promptly and functions as the body’s 
first line of defense by providing physical barriers and reacting to common danger signals 
associated with infection and cell damage. Once established, however, the adaptive 
immune response against e.g. a microorganism in most cases efficiently eradicates the 
intruder. In addition, the adaptive immune system has the capacity to generate 
immunological memory in the form of circulating long-lived cells that are ready to 
initiate a quick immune response if the same antigen is encountered again at a later time 
point. This allows the removal of pathogens previously encountered by the immune 
system before illness arises. 
The adaptive immune system comprises T and B lymphocytes, which both express 
antigen-specific receptors on their surface. These receptors are generated by 
recombination of a large selection of DNA segments into single functional genes. Since 
this process takes place in a random way within each cell, it ensures great variability 
within the T- and B-cell populations. As a result of the recombination process, each cell 
has receptors with a single, defined specificity that differs from the specificity of most 
other T- and B-cells in the body. 
The receptors on T and B cells recognize different types of antigens. T-cell 
receptors (TCRs) bind peptide antigens when bound to major histocompatibility complex 
(MHC) molecules on the surface of other cells. The CD8+ subset of T cells binds peptides 
in complex with MHC class I molecules, whereas the CD4+ subset binds peptides 
together with MHC class II molecules. As a result, CD8+ T cells can recognize antigen 
displayed on the surface of any nucleated cell that presents peptides derived from 
endogenous proteins. CD4+ T cells, on the other hand, only interact with specialized, 
antigen-presenting cells (APCs) that take up antigen from their surroundings and 
8subsequently process and display it on their surface. MHC class II-expressing APCs 
include B cells as well as dendritic cells (DCs) and macrophages, which belong to the 
innate immune system. Some APCs can also display exogenous antigen on MHC class I 
molecules through a mechanism known as crosspresentation, thus allowing them to 
provide activation signals to CD8+ T cells. While TCRs are restricted to binding protein 
antigens, B-cell receptors (BCRs) can interact with any type of molecule, since B cells 
recognize intact antigens and do not depend on presentation on MHC molecules.  
The different contexts in which the cells of the adaptive immune system recognize 
antigen reflect their different effector functions. CD8+ T cells can interact with most cells 
in the body and thus has the capacity to detect virus-infected or transformed cells. 
Through the release of cytotoxic substances CD8+ T cells can kill such cells and thereby 
eliminate the threat. CD4+ T cells interact with other immune cells that have been in 
touch with antigen, and they play an important role in the modulation of immune 
responses through the release of various cytokines. The primary function of B cells is to 
produce antibodies. These are soluble, secreted versions of the BCR that bind antigen, 
resulting in the formation of immune complexes. These complexes can activate 
components of the innate immune system like the complement system and macrophages 
that bind antibodies via Fc receptors on their surface, leading to elimination of the 
antigen. Antibody binding to antigen can also have a more direct effect, e.g. by interfering 
with the function of important surface molecules on microorganisms. In most cases, the 
activation of B cells to become antibody-secreting cells requires help from CD4+ T cells 
and also depends on antigen presentation by innate immune cells. Hence, it illustrates the 
close interdependence that exists between different types of cells, both adaptive and 
innate, within the immune system. 
Because of the powerful effects of the adaptive immune system it is crucial that 
immune responses are only generated against foreign antigens. To ensure that self-
antigens are not targeted by the adaptive immune system, mechanisms that ensure 
tolerance to the body’s own molecules exist. Despite close control of development and 
activation of T and B cells, these mechanisms sometimes fail. As a result, the immune 
system can launch an attack against self-derived antigens, and autoimmunity arises. 
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B-cell development 
Both T and B cells originate from common lymphoid progenitor cells in the human bone 
marrow. In order for a progenitor (pro)-B cell to develop into a B cell, it needs to undergo 
a process culminating in the expression of a functional BCR consisting of two 
immunoglobulin (Ig) heavy (H) chains and two light (L) chains [1]. The C-terminal part 
of the H chains contains a membrane-spanning domain that attaches the receptor to the 
cell surface. Each H and L chain consists of a variable region and a constant region. The 
H chain constant region can be made up of different polypeptide chains. These are named 
α, δ, ε, γ and μ and correspond to the different isotype classes that describe whole Ig 
molecules: IgA, IgD, IgE, IgG and IgM.  Some classes have more than one member. 
Thus, in humans there are two subtypes of IgA, IgA1 and IgA2, and four subtypes of IgG, 
IgG1-4. In contrast to the H chain, which is encoded in a single locus, the L chain can be 
expressed from one of two loci named κ and λ, which give rise to different polypeptide 
chains. Together, the variable regions of one H and one L chain form a single antigen 
binding site, thus making the BCR a bivalent molecule (Fig. 1). 
Igα/IgβH chain
L chain
Antigen
P
P P
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A B
Figure 1. General structure and signaling mechanism of the BCR complex. (A) Each Ig H and L chain 
consists of a constant region (dark red) and a variable region (golden). The two H chains and each pair of H 
and L chains are connected by disulfide bonds (not shown), and the H chains are attached to the cell surface 
through a membrane-spanning region. In addition, the two H chain constant regions associate with a single 
Igα/Igβ heterodimer through noncovalent interactions. (B) Binding of multivalent antigen to the Ig variable 
regions leads to clustering of BCRs. This, in turn, is believed to result in phosphorylation of specific 
tyrosine residues in the cytosolic domains of Igα and Igβ by the Src-family kinase Lyn, which thereby 
initiates an intracellular signaling cascade. 
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In order for a developing B cell to express a BCR it needs to carry out genetic 
rearrangements in the Ig loci, resulting in the joining of a V, a D and a J gene segment in 
the H chain locus and a V and a J segment in one of the L chain loci [2]. This process is 
initiated by the products of the recombination activating genes, RAG-1 and RAG-2 [3, 4]. 
Together, the joined gene segments encode the variable regions of the BCR. Since the 
variable regions represent random combinations made from a large pool of available gene 
segments, the recombination process leads to the development of a repertoire of B cells 
with diverse specificities. In addition, extra nucleotides can be added in the junctions 
between the segments, giving rise to even higher diversity [5].
Once successful recombination has taken place at the H chain locus, the cell is 
called a precursor (pre)-B cell and starts to express a μ H chain, which associates with an 
invariant heterodimer known as the surrogate L chain (Fig. 2). This complex, the pre-
BCR, is capable of inducing signaling that allows further progression in B-cell 
development [6]. Signaling through the pre-BCR occurs, like signaling through the 
mature BCR, by phosphorylation of the membrane-spanning Igα/Igβ heterodimer, which 
is tightly associated with the H chain [7] (Fig. 1). It is believed that the phosphorylation is 
triggered by clustering of receptor molecules in the cell membrane and that extensive 
clustering is induced by binding of multivalent antigens [8, 9]. However, the B cell is 
dependent on weak signaling through the BCR at all times in order to survive [10]. This 
tonic signaling is independent of antigen binding and has been suggested to arise from 
spontaneous oligomerization of BCRs in the plasma membrane or stochastic activation of 
kinases that phosphorylate the cytosolic tails of Igα/Igβ [11]. Recently it has been shown 
that BCR signaling correlates with diffusion of BCR molecules in the membrane of 
resting B cells and that receptor diffusion is controlled by the actin cytoskeleton [12].  
Tonic signaling therefore seems to be limited by restrictions in BCR movement imposed 
by the underlying cytoskeleton. Binding of multivalent antigen could make BCRs 
overcome these restrictions and, thus, lead to increased signaling, ultimately resulting in 
B-cell activation. 
Rearrangements in the L chain loci happen after the H chain rearrangements are 
completed [13]. Upon successful recombination, the cell becomes an immature B cell and 
starts expressing either a κ or a λ L chain that pairs with the μ H chain, resulting in the 
formation of a mature BCR (Fig. 2). At this point the cell leaves the bone marrow and is 
also called a transitional B cell [14]. During the final stages of development, the BCR is 
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tested for autoreactivity in order to avoid maturation of autoreactive B cells, and the cell 
acquires IgD on its surface. The δ H chain is expressed through alternative splicing of a 
primary transcript containing both the μ and δ chain sequence. As a result, mature B cells 
express both IgM and IgD and have both types of BCR on their surface (Fig. 2). The 
variable regions are identical for the two isotypes, thus giving them the same antigen 
specificity, and it is not clearly understood why mature B cells express both IgM and IgD 
[15].
CLP
Pro-B cell Pre-B cell Immature B cell Mature 
naïve B cell
Pre-BCR IgM IgM
IgD
Isotype-switched BCR
Plasma cell
Memory B cell
Bone marrow
Secreted
antibodies
Periphery
Figure 2. Stages in B-cell development. Both B and T cells originate from common lymphoid progenitors 
(CLPs) in the bone marrow. Upon gene rearrangements in the H chain locus, the developing B cell starts 
expressing a surface-bound pre-BCR comprising a μ H chain and the surrogate L chain. The latter is a 
heterodimer consisting of the proteins VpreB1 and λ5. When successful gene rearrangements have been 
carried out in one of the L chain loci, a mature IgM BCR is expressed on the cell surface. After leaving the 
bone marrow, the still immature B cell is said to be transitional (not shown), and its BCR is tested for 
reactivity to peripheral self-antigens. Once it reaches the mature stage, the B cell expresses both IgM and 
IgD on the surface and migrates to the follicles of secondary lymphoid organs. Upon encounter with 
cognate antigen, follicular B cells start proliferating and differentiate into antibody-secreting plasma cells 
and memory B cells, some of which will carry isotype-switched Ig genes. Some of the generated plasma 
cells return to the bone marrow, where they can continue to secrete antibodies for years. If the same antigen 
is encountered a second time, circulating memory cells differentiate into plasma cells, leading to rapid 
production of high amounts of antibody.
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Mature lymphocytes that have not yet encountered antigen are called naïve. In their 
search for antigen, naïve B and T cells populate the secondary lymphoid organs: spleen, 
lymph nodes, Peyer’s patches and tonsils. Here, the B cells are organized into follicles,
whereas the T cells have their own T-cell zones (Fig. 3). Antigen that enters the body is 
delivered to the secondary lymphoid organs, where it can be recognized by lymphocytes. 
Upon exposure to antigen, cognate T and B cells can interact with each other, leading to 
their mutual activation and, in most cases, efficient clearance of the antigen [16]. 
Naïve B cell
Antigen
Tfh
FDC
Follicle
T-cell zone
GC
CD4   T cell+
Memory B cell
Antigen-
stimulated
B cell
Extrafollicular response 
GC response
Plasma cell
Figure 3. Overview of B-cell activation by T-cell dependent antigens. Follicular B cells that receive BCR 
stimulation through binding of antigen migrate to the border between the follicle and the T-cell zone in 
response to the chemokines CCL19 and CCL21, which bind to the upregulated receptor CCR7. Through 
presentation of antigen on their surface the B cells can make contact with cognate CD4+ T cells, leading to 
mutual B- and T-cell activation. After initial proliferation at the periphery of the follicle, B cells can either 
differentiate into plasma cells and memory B cells directly at this site and thereby take part in an 
extrafollicular response or establish a GC inside the follicle. Here B cells interact with FDCs, which 
accumulate antigen in the form of immune complexes on their surface. Antigen received from FDCs is 
subsequently presented by GC B cells to Tfhs, which provide the B cells with survival signals. During the 
GC reaction the proliferating B cells mutate their BCR, leading to a gradual increase in affinity for antigen. 
Upon differentiation, GC B cells thereby give rise to high-affinity plasma cells and memory B cells.
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B-cell activation and antibody production 
B cells residing in secondary lymphoid tissues can encounter antigen either in the form of 
soluble molecules or as receptor-bound complexes on the surface of APCs. The 
prevailing view is that B cells most often respond to membrane-bound antigen, which can 
accumulate on the surface of subcapsular sinus macrophages or DCs in lymph nodes [9]. 
These innate immune cells might be able to present intact antigen to B cells via binding of 
immune complexes to Fc or complement receptors, thereby allowing a single cell to 
display multiple antigen molecules. In this way, even antigen that is monomeric in nature 
can cause clustering of BCRs upon binding and thereby induce B-cell signaling.
B cells that have “seen” antigen and are signaling through their BCR increase 
expression of the chemokine receptor CCR7, resulting in migration to the junction 
between the follicle and the T-cell zone, where the B cells can interact with T cells and 
proliferate [17, 18] (Fig. 3). The B cells take up antigen bound to their BCR through 
receptor-mediated endocytosis. Following lysosomal processing, peptides derived from 
the endocytosed antigen are bound to MHC class II molecules and displayed on the cell 
surface [19]. This allows antigen-specific CD4+ T cells to interact with the B cells and 
provide activation signals that induce B-cell proliferation and differentiation. Signaling 
induced by the B-cell membrane protein CD40 upon interaction with CD40 ligand on T 
cells is of particular importance and ensures specific activation of B cells that can pair 
with cognate T cells [20]. At this point some of the activated B cells differentiate into 
plasma cells that secrete high levels of antibody [16]. The antibodies are generated 
through alternative splicing, replacing the trans-membrane part of the BCR with a 
secretory tail. This first wave of antibodies consists mostly of IgM molecules with 
relatively low affinity for antigen. 
Some of the activated B cells establish a site within the follicle at which extensive 
proliferation is taking place in an antigen-dependent manner (Fig. 3). This is known as the 
germinal center (GC). Here, B cells interact with a particular CD4+ T-cell subset known 
as follicular T helper cells (Tfhs) [21], and they are continuously provided with antigen 
by specialized follicular dendritic cells (FDCs) [22]. Although FDCs efficiently 
accumulate antigen on their surface, their presence is not required for establishment of the 
GC [23], suggesting that B cells can be provided with antigen from other sources. The 
signals B cells receive from T cells induce two processes that both depend on expression 
of the enzyme activation-induced cytidine deaminase: somatic hypermutation (SHM) and 
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class-switch recombination (CSR) [24]. During the GC reaction, B cells undergo rounds 
of cell division accompanied by SHM, leading to the introduction of mutations in the Ig 
variable regions. Some of these mutations will cause a rise in BCR affinity for the 
antigen. This property is continuously tested in the GC, making sure that high-affinity B 
cells are selectively activated at the expense of those with lower affinity. The main 
principle underlying this selection process is believed to be the competition between GC 
B cells for limited access to Tfhs [25-27]. B cells with higher affinity BCRs are more 
efficient in taking up and presenting antigen and thus have an advantage in the 
competition for Tfh interactions. Since these interactions are necessary for B-cell survival 
in the GC, the cells undergo an affinity maturation process, during which the affinity of 
the BCR is gradually increased. 
The switching of Ig isotype caused by CSR is initiated before activated B cells enter 
the GC but can continue during the GC reaction [28, 29]. The recombination process 
results in the replacement of the H chain constant region so that the μ sequence is 
exchanged with one of the other isotypes. The different Ig classes provide different 
effector functions to secreted antibodies, and the choice of isotype largely reflects the 
nature of the antigen and the context in which it is encountered. For example, antigens 
that enter the body through mucous membranes primarily give rise to IgA-secreting 
plasma cells. These cells migrate from their induction site, the secondary lymphoid 
tissues, to the antigen entrance site and start secreting large amounts of IgA antibodies. 
Most of this IgA is produced in a dimeric form that can be transported across the mucosal 
epithelium, thus allowing the neutralization of antigen present in the outside lumen [30]. 
The outcome of the GC reaction is high-affinity, isotype-switched, long-lived 
plasma cells and memory B cells. Upon re-exposure to antigen, circulating memory B 
cells can differentiate into plasma cells, thereby allowing rapid production of large 
amounts of high-affinity antibodies. Even in the absence of antigen, memory B cells can 
give rise to plasma cells, suggesting that the plasma cell population is continuously 
replenished from polyclonally activated memory cells [31]. This might explain how 
production of specific antibodies can be sustained for a human life time without re-
exposure to the triggering antigen [32]. In the same way as plasma cells, memory B cells 
can also be generated from non-GC B cells. The resulting memory cells typically carry 
unswitched, unmutated Ig genes [33, 34]. It is unclear what determines if a B cell will 
enter a GC reaction or take part in an extrafollicular response, and usually both types of 
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response arise in parallel [35]. The decision could be a stochastic one, but it appears that 
the GC fate depends on the B cell being able to make interactions with T cells [36]. 
So far, I have described the activation of B cells as being dependent on T-cell help. 
This, however, is not always the case as some antigens can induce T cell-independent (TI) 
antibody responses. These can be divided into type 1 and type 2 responses. In addition to 
the stimulation provided through binding of the BCR, TI-1 antigens can provide a second 
signal by engaging Toll-like receptors, which recognize certain microbial products, 
leading directly to B-cell activation [37]. TI-2 responses, on the other hand, are generated 
against antigens with repetitive epitopes, such as polysaccharides, that cause extensive 
BCR aggregation upon binding to B cells [38]. TI responses are typically generated 
extrafollicularly but can in some cases be associated with GC formation [39, 40]. Such 
GCs, however, only exist for a short period of time before they disintegrate. Without the 
help of T cells, GC B cells with high-affinity BCRs cannot be selected, and the affinity 
maturation process is abrogated. 
Autoreactive B cells 
Lymphocytes are controlled for reactivity to self-antigens at different stages in their 
development, and several negative selection mechanisms are in place to prevent the 
activation of autoreactive clones; i.e. to maintain self tolerance [41, 42]. It has been 
shown that more than half of human early immature B cells recognize self-antigens [43], 
thus illustrating the inherent potential of V(D)J recombination to generate autoreactive 
receptors and the importance of efficient control mechanisms. In the bone marrow, 
immature B cells “sense” if they are autoreactive through BCR signaling. Strong 
clustering of BCR molecules induced by binding to self-antigen causes the B cell to 
attempt to get rid of its autoreactivity by receptor editing [44]. This is achieved by 
continued gene rearrangements in the L chain loci, allowing the replacement of the old 
BCR L chain with a new one. If this does not result in the loss of self-reactivity, the B cell 
undergoes apoptosis and is thereby deleted from the repertoire. Transitional B cells pass 
through a second “checkpoint” in the periphery where the BCR is tested for reactivity to 
self-antigens that are not expressed in the bone marrow and autoreactive clones are 
removed [43].  
From studies done in mice, it is known that only B cells carrying receptors that are 
efficiently aggregated by self-antigen are deleted from the repertoire. In contrast, BCRs 
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that only become weakly aggregated or bind self-antigen with low affinity induce a state 
of unresponsiveness, anergy, in B cells [45-47]. Anergic B cells are present in the 
periphery and populate secondary lymphoid tissues. However, they have a decreased life 
span and remain unresponsive to self-antigen. Since the cellular changes associated with 
anergy are reversible, it has been speculated, though, that anergic B cells can contribute to 
autoimmunity under some circumstances [47].  
In agreement with the central role of BCR signaling in determining the fate of 
developing B cells, it has been observed that the form in which a self-antigen exists has a 
strong impact on the induction of tolerance. Thus, membrane-bound self-antigens, which 
are multivalent in nature, can induce clustering of BCRs and thereby efficient negative 
selection of cognate B cells [48, 49]. Soluble self-antigens, on the other hand, do not 
cause BCR clustering, thereby allowing cognate B cells to escape negative selection. As a 
result B cells recognizing soluble self-antigen are present in the periphery and maintain 
their potential to become activated [49]. Normally, such B cells do not give rise to 
autoantibodies, though, because they do not receive the necessary T-cell help. T cells 
therefore hold the key to keep autoreactive B cells in an inactive state, and autoantibody 
production will require either breaking of T-cell tolerance or engagement of non-cognate 
T cells in providing activation signals to autoreactive B cells.  
Despite the various control mechanisms that are in place to ensure self tolerance, it 
does happen that B cells recognizing self-antigens are activated and differentiate into 
autoantibody-producing plasma cells. This is the case in the gluten-sensitive enteropathy 
celiac disease, in which autoantibodies targeting the enzyme transglutaminase 2 (TG2) 
are produced. 
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CELIAC DISEASE 
Pathogenesis
Celiac disease is caused by an inappropriate immune response against cereal gluten 
proteins found in wheat, barley and rye. The presence of the causative antigens in the diet 
results in destruction of the small intestinal epithelium and can lead to malabsorption. The 
disease is characterized by histological changes that can be observed in small intestinal 
biopsies, including villous atrophy, crypt cell hyperplasia and increased numbers of 
intraepithelial lymphocytes [50]. Celiac disease affects around 1% of the population in 
the Western world [51-53] and seems to be increasing in prevalence [54]. It can occur at 
all ages, but apart from the requirement of a gluten-containing diet it is unclear what 
factors affect onset of the disease. 
The increased incidence of celiac disease observed among close family members of 
diagnosed individuals suggests a strong genetic component in the disease [53, 55, 56]. 
Genome-wide association studies have revealed that many different genes are involved, 
and it is most likely the combination of several genetic variants that confers susceptibility 
to disease development [57-60]. By far the most important contribution, however, is made 
by members of the human leukocyte antigen (HLA) group of genes. In particular, certain 
alleles encoding variants of the MHC class II molecule HLA-DQ have been found to play 
an essential role [61, 62]. Hence, the great majority of individuals diagnosed with celiac 
disease express the variant HLA-DQ2.5 encoded by the DQA1*05 and DQB1*02 alleles, 
and most of the remaining patients express HLA-DQ8 encoded by DQA1*03 and 
DQB1*03:02.
The involvement of MHC class II molecules suggests that T cells are important for 
the pathogenesis. In line with this notion, CD4+ T cells recognizing gluten-derived 
peptides in the context of HLA-DQ2.5 or HLA-DQ8 can be found in the small intestinal 
mucosa of celiac disease patients [63-65]. It is believed that these T cells orchestrate the 
immune response that leads to the destruction of the epithelium through the release of 
proinflammatory cytokines like interferon (IFN)-γ [66]. The actual killing of enterocytes 
is mediated by CD8+ cytotoxic T cells that interact with non-classical MHC class I 
molecules on target cells through expression of activating natural killer cell receptors 
[67]. Upregulation of the recognized proteins on enterocytes and stimulation of T-cell 
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cytotoxicity were shown to be induced by interleukin (IL)-15 [68, 69], which is expressed 
at increased levels in the intestinal mucosa of celiac disease patients [70].  
Under normal conditions, the microenvironment of the intestinal mucosa does not 
support the generation of inflammatory immune responses against food proteins, a 
phenomenon known as oral tolerance [71]. By overexpression of IL-15 in the intestinal 
epithelium of mice, it was shown, however, that the cytokine in combination with retinoic 
acid can lead to disruption of oral tolerance, possibly explaining why gluten induces an 
inflammatory rater than tolerogenic response in celiac disease [72]. Alternatively, IFN-α,
which is also upregulated in the small intestinal mucosa of celiac disease patients, could 
be involved in promoting an inflammatory T-cell response and thereby cause breaking of 
gluten tolerance [73]. 
The gluten peptide antigens targeted by CD4+ T cells are different from most other 
protein-derived peptides as they are extremely rich in glutamine and proline residues. The 
high proline content makes them resistant to digestion by gastrointestinal proteases, 
meaning that long fragments reach the small intestine, where they can induce an immune 
response [74]. Another important feature of gluten peptides is their ability to serve as 
substrates to extracellular TG2, which is found abundantly beneath the intestinal 
epithelium [75]. This leads to the enzymatic conversion of specific glutamine residues 
into glutamic acid through a reaction known as deamidation. Notably, the CD4+ T-cell 
response in celiac disease targets deamidated rather than native gluten peptides, implying 
that TG2-mediated deamidation plays a central role in the disease induction [75, 76]. 
Curiously, though, the same enzyme, which is responsible for generating T-cell epitopes, 
has turned out also to be a target of celiac disease autoantibodies [77]. 
Antibodies in celiac disease 
Compared to healthy tissue, the lamina propria of the celiac disease lesion contains 
increased numbers of plasma cells, most of which secrete IgA antibodies [78]. In 
addition, both IgA and IgG antibodies targeting specific antigens can be found in serum 
samples from celiac disease patients [79]. Not surprisingly, these include antibodies 
against gluten. In line with the central role of deamidation for the generation of T-cell 
epitopes, serum antibodies recognizing deamidated versions of gluten peptides can also 
be detected. Such antibodies have been found to be more specific to celiac disease than 
antibodies against native, non-deamidated gluten [80, 81]. The most sensitive and specific 
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serological tests, however, are based on detection of autoantibodies against TG2 [82]. 
Both IgA and IgG antibodies targeting TG2 can be detected in serum, but the IgA test has 
been found to be more sensitive and is most widely used. IgA deficiency, however, is 
observed more frequently among celiac disease patients than in the general population 
[83], and in those cases the IgG test becomes very useful [84]. As a consequence of the 
high accuracy of anti-TG2 tests, the guidelines of the European Society for 
Gastroenterology and Hepatology now approve diagnosis of childhood celiac disease 
based on detection of TG2-specific serum antibodies [85]. Hence, it is no longer 
mandatory to take a small intestinal biopsy in order to diagnose children who express 
HLA-DQ2.5 or HLA-DQ8 and have high titres of TG2-specific serum antibodies.  
The autoimmune component of celiac disease has been known for more than 40 
years and was first observed in the form of serum antibodies targeting connective tissue 
fibers [86]. Depending on which structures were recognized, the antibodies were called 
reticulin antibodies [87, 88] or endomysial antibodies [89]. In 1997 Schuppan and 
coworkers identified TG2 as the target of the endomysial antibodies [77], and it was later 
shown that the reticulin antibodies also recognize this enzyme [90]. The discovery that 
TG2 is the main autoantigen in celiac disease represents a major step forward in the 
molecular dissection of this complex autoimmune disorder and has led to the 
development of enzyme-linked immunosorbent assays (ELISAs) that allow rapid 
detection of the autoantibodies [91, 92]. 
In addition to the antibodies found in serum, anti-TG2 IgA can be detected in the 
form of deposits in the intestinal mucosa [93]. Such deposits have been observed even in 
the rare cases of celiac disease without detectable TG2-specific serum antibodies, 
suggesting that antibodies targeting TG2 are produced by everyone affected by the 
disease [94]. Furthermore, the deposits have been shown to predict developing celiac 
disease, as they are present before intestinal damage occurs [95]. The tight connection 
between the development of celiac disease and production of TG2-specific autoantibodies 
suggests that the activation of TG2-reactive B cells could play a central role in the 
pathogenesis. Whether the enzymatic activity of TG2 is directly involved in this process, 
as is the case for the generation of T-cell epitopes, remains to be seen. 
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TRANSGLUTAMINASE 2 
Structure and function 
The primary function of the nine human transglutaminases is to catalyze the Ca2+-
dependent formation of Nε(γ-glutamyl)lysine isopeptide bonds, thereby mediating the 
crosslinking of two polypeptide chains and the production of stable, covalently linked 
complexes [96]. TG2 is involved in the crosslinking of proteins in the extracellular matrix 
(ECM), including the basement membrane components entactin, osteonectin, fibronectin 
and collagen type VII [97]. This process is believed to be important for the stabilization 
of the ECM structure. Further, TG2 crosslinking activity has been implicated in the 
activation of transforming growth factor-β [98, 99] and the formation protein aggregates 
in apoptotic cells [100, 101].
TG2 reacts with glutamine residues in specific sequence contexts [102, 103]. 
Gluten-derived peptides are rich in glutamines and many are extremely good substrates 
for TG2 [104, 105]. These peptides are also rich in proline residues, and it has been 
shown that the distance between a glutamine residue and proline to a large degree 
determines if the glutamine is targeted by TG2. Thus, glutamines residing in QXP motifs 
(where X can be any amino acid) are preferred substrates for the enzyme, whereas 
glutamines found in the sequence QP or QXXP are not targeted [106]. The reaction 
between the active-site cysteine in TG2 and the side chain of a glutamine residue results 
in the formation of a thioester intermediate accompanied by the release of ammonia [96]. 
This intermediate is subsequently resolved through a reaction with a primary amine that 
serves as an acyl acceptor, leading to the formation of an isopeptide bond and re-
establishment of a free active-site cysteine thiol. The process is known as transamidation 
and can either involve a small-molecule amine or a polypeptide lysine residue as the acyl 
acceptor substrate. In the absence of available amine substrates, the acyl-enzyme 
intermediate is hydrolyzed, leading to deamidation of the glutamine residue. Deamidation 
also appears to be the favored reaction under mildly acidic conditions [107]. As the 
reaction that leads to transamidation is reversible, TG2 has the capacity to break already 
formed isopeptide bonds and either form new ones or deamidate the involved glutamine 
residues [108-110]. This suggests that the TG2-mediated formation of protein-protein 
crosslinks is dynamic and allows re-shaping of the ECM structure through shuffling or 
hydrolysis of isopeptide bonds. 
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Apart from the roles TG2 plays through its transglutaminase activity, the protein 
has been implicated in a number of other processes. In the ECM, TG2 makes a strong, 
non-covalent interaction with fibronectin [111], but the enzyme is also found on cell 
surfaces where it associates with integrins of the β1 and β3 subfamilies or heparan sulfate 
proteoglycans [112-115]. By forming ternary complexes with membrane proteins and 
fibronectin, TG2 can function as a bridge between the cell surface and the ECM. Such 
complexes are involved in cell adhesion and migration, and their formation appears to be 
fundamental in wound healing [116]. Several other TG2 interaction partners have been 
described, although the functional implications for these are not as well understood. 
Presumably, TG2 can take part in several different cell-ECM interactions, thereby 
mediating various kinds of cellular attachment or signaling depending on the cell type 
[117].
Although the functions described above all relate to the extracellular environment, 
the majority of TG2 is found inside cells. Here, it is mainly present in the cytosol, but 
small amounts also localize to the nucleus and mitochondria [118]. Intracellularly, TG2 
binds and hydrolyzes GTP and functions as a G-protein involved in signaling through 
phospholipase C [119]. The binding of GTP/GDP has been shown to inhibit Ca2+-induced
activation of TG2 [120]. Hence, due to low levels of Ca2+ and high levels of GTP/GDP in 
the cytosol, intracellular TG2 does not have transglutaminase activity under normal 
physiological conditions [121]. However, it has been suggested that cytosolic TG2 can 
become activated during signaling events that lead to a transient rise in the local 
concentration of Ca2+ [122]. In addition, TG2 might have other enzymatic functions. 
Hence, the enzyme has been described to work both as a kinase [123] and as protein 
disulfide isomerase [124]. 
TG2 is a 77 kDa, monomeric protein consisting of four structural domains: an N-
terminal β-sandwich, a complex-fold core domain, which contains the transglutaminase 
active site as well as five putative Ca2+ binding sites [125], and two C-terminal β-barrels. 
The three-dimensional structure of the enzyme has been solved in two different 
conformations. In the structure of TG2 with a bound GDP molecule, the enzyme adopts a 
“closed” conformation in which the two C-terminal domains are folded in on the core 
domain and cover the active site [126]. A very similar structure was obtained for TG2 
with bound ATP [127]. Crystallization of TG2 with a peptide inhibitor covalently 
attached to the active-site cysteine, on the other hand, revealed an “open” conformation 
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with the four domains aligned to make up an extended structure [128]. The closed 
conformation is induced by GTP/GDP binding, whereas the enzyme “opens up” in the 
presence of Ca2+ [129, 130]. The open conformation, however, was crystallized without 
bound Ca2+ ions, and the true structure of the catalytically active enzyme is therefore not 
known.
Expression and regulation 
TG2 can be detected in all organs and is constitutively expressed by ubiquitous cell types 
such as endothelial cells and smooth muscle cells [131]. Moreover, its expression is 
induced in many other cell types during cellular maturation or differentiation, and it is 
also induced in apoptotic cells [100, 132-134]. The enzyme is found abundantly in the 
intestine where it associates with the ECM beneath the epithelium. It has been reported 
that TG2 expression is upregulated in the small intestine of celiac disease patients and 
that the distribution of the enzyme in the tissue varies from that of healthy individuals 
[75, 104, 135-137]. Given the ubiquitous expression and diverse functional roles of TG2, 
it came as a surprise that disruption of the TG2 gene does not lead to a severely altered 
phenotype in mice [138, 139]. The explanation for this is presumably that other pathways 
are in place to take over the functions of TG2.  
TG2 is translated in the cytosol, and the amino acid sequence does not include a 
signal peptide that directs the protein for secretion via the traditional route through the 
endoplasmic reticulum. Hence, the enzyme reaches the extracellular environment by an 
unconventional, poorly understood mechanism. It was recently proposed that the 
secretion involves binding of cytosolic TG2 to phospholipids on recycling endosomes, 
followed by the association of TG2 with integrins inside the endosomes and, ultimately, 
emergence of the TG2-integrin complexes on the cell surface [140]. How TG2 crosses the 
endosomal membrane, however, remains unknown. 
Despite a high Ca2+ concentration in the extracellular environment, 
transglutaminase activity cannot be detected in mouse small intestine under normal 
conditions in vivo [141, 142]. Upon induced tissue injury, however, TG2 activity could 
readily be observed, suggesting that either the enzyme is modified in a way that allows its 
activity to be turned on and off or active enzyme is released from damaged cells. In line 
with the former option, oxidation is known to affect the activity of TG2, and it was found 
that the engagement of Cys370 in disulfide bond formation either with its neighbor 
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Cys371 or with Cys230 results in loss of transglutaminase activity [143]. The active 
enzyme can be restored by reduction, and it was later shown that this process can be 
carried out by the redox protein thioredoxin, which is normally present in the cytosol but 
can be released and found in the extracellular environment during inflammation [144]. It 
is likely that secreted TG2 is inactivated after it reaches the oxidizing extracellular 
environment but can become re-activated during inflammation or cell damage as a result 
of a local shift in the redox environment. In celiac disease, where an ongoing 
inflammation is occurring, it is therefore possible that extracellular TG2 is active and can 
be engaged in deamidation of gluten peptides. 
Characteristics of TG2-specific autoantibodies 
Several attempts have been made to find out if the antibodies targeting TG2 have a 
pathogenic role in celiac disease. Immunization of mice with human TG2 resulted in the 
production of TG2-specific antibodies but did not lead to intestinal damage [145]. Neither 
did adenovirus-mediated expression of TG2-specific single-chain antibody fragments in 
mice [146]. Nevertheless, by adding antibodies from celiac disease patients to cell-culture 
systems, various effects have been reported. These include induction of proliferation 
[147] and inhibition of differentiation [148] in epithelial cells, suggesting that some 
histological features observed in small intestinal biopsies from celiac disease patients 
could be a result of autoantibody production. In another study it was shown that serum 
antibodies targeting TG2 can induce monocyte activation and increase epithelial 
permeability, thereby supposedly contributing to leakiness of the intestinal epithelium and 
induction of the anti-gluten immune response [149]. It has also been found that celiac 
disease serum antibodies can inhibit angiogenesis in vitro [150] and increase vascular 
permeability [151]. The latter effect was shown to result from increased transglutaminase 
activity upon binding of autoantibodies to TG2 [151].
Other studies have addressed the direct effect of TG2-specific autoantibodies on the 
activity of the enzyme. It was first reported that autoantibodies from celiac disease 
patients inhibit the transamidation activity of TG2 [152]. However, the implications of 
antibody binding for TG2 activity in vivo was later questioned, as only very limited 
inhibition could be observed [153]. As mentioned above, increased TG2 activity has also 
been reported upon binding of autoantibodies [151, 154], and recently it was shown that a 
panel of TG2-specific monoclonal antibodies (mAbs) generated from plasma cells in the 
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celiac lesion does not affect the transamidation and deamidation activities of the enzyme 
[155]. Taken together, these studies indicate that the TG2-targeting autoantibodies in 
celiac disease have little if any effect on transglutaminase activity. Most likely, the 
discrepancies in the reported results can be ascribed to differences in the employed 
assays. Hence, it is possible that antibody binding can influence TG2 reactivity with 
certain substrates due to steric effects. 
TG2-specific mAbs derived from intestinal lymphocytes of celiac disease patients 
have been generated in two independent studies [155, 156]. In 2001, Marzari et al. 
reported the use of phage-display libraries to obtain TG2-specific antibody fragments 
[156]. TG2-reactive fragments could be found in libraries generated from lymphocytes of 
the small intestine but not in libraries from peripheral blood lymphocytes. Among the 
TG2-specific clones, the authors found an overrepresentation of antibodies using the 
VH5-51 gene segment. This feature was confirmed in a study published last year by Di 
Niro et al. who cloned H and L chain variable regions from single-cell sorted, TG2-
specific plasma cells of the celiac disease intestinal lesion [155]. Compared to the phage-
display method this approach has the advantage that it generates authentic antibodies with 
the correct pairing of H and L chains. Surprisingly, despite the immune response being 
chronic, the TG2-specific mAbs were found to have few somatic mutations compared to 
the level of mutations found in other B-cell populations. Reversion of selected mAbs to 
their germline configuration, however, showed that the mutations that had accumulated 
increased the affinity of the antibodies for TG2. This suggests that TG2-specific B cells 
go through an affinity maturation process, but, for some reason, the GC reaction leading 
to SHM is limited. 
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AIMS
The overall goal of the study was to understand the molecular mechanisms underlying the 
production of autoantibodies targeting TG2 in celiac disease. This should be achieved 
through detailed characterization of the interaction between TG2 and antibody using a 
previously generated panel of TG2-specific mAbs [155]. Specifically, we have aimed to 
address the following points: 
• TG2 can exist in several different forms. It can take an open or a closed 
conformation, it can be bound to fibronectin, and it can be associated with cell 
membranes. Do the antibodies discriminate between these different forms? 
Answering in which state the enzyme is antigenic will give us an indication of 
how the initial meeting between autoreactive B cells and TG2 takes place. 
• Which regions in TG2 are involved in binding to autoantibodies? Epitope 
mapping should allow us to answer if there are common patterns that are 
recognized by the antibodies and provide us with a deeper understanding of how 
B cells interact with TG2. 
• The finding that binding between TG2 and autoantibodies does not result in loss 
of transglutaminase activity raises the possibility that TG2 is catalytically active 
when bound to antibodies or BCRs. Can TG2-mediated crosslinking on the 
surface of B cells be implicated in B-cell activation and initiation of the anti-TG2 
response? By studying the potential role of Ig molecules as substrates for the 
enzyme we can envisage models that couple TG2-BCR binding to collaboration 
between TG2-specific B cells and gluten-specific T cells. Specifically, TG2-
mediated crosslink formation between gluten-derived peptides and BCR 
molecules on TG2-specific B cells provides a possible explanation for how gluten 
intake leads to the production of autoantibodies against TG2. 
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SUMMARY OF PAPERS
Paper I 
The binding between celiac disease autoantibodies and TG2 was characterized by using a 
panel of 57 mAbs generated by cloning of antibody variable regions from TG2-specific 
plasma cells in patient small intestinal biopsies [155]. We show that the mAbs are highly 
specific to TG2, and many bind stronger to the open than the closed enzyme 
conformation. Further, by letting the mAbs compete with each other for binding we show 
that there are few common epitopes and that these are clustered together. Two of the 
epitopes were overlapping with the fibronectin binding site in the N-terminal domain of 
TG2 and one epitope could be disrupted by the introduction of mutations previously 
reported to interfere with the binding of TG2-specific serum antibodies [157]. Since none 
of the epitopes was accessible on cell surface-bound TG2, we propose that the clustering 
of epitopes in a small region of TG2 can be explained by negative selection of B cells 
recognizing epitopes that are not blocked on the surface of cells. 
Paper II 
In order to get a more detailed understanding of the interaction between TG2 and 
antibodies we employed hydrogen/deuterium exchange mass spectrometry to monitor the 
solvent accessibility of TG2 regions in the presence or absence of mAbs. In this way we 
were able to pinpoint antibody binding sites. In addition, we saw that mAbs binding 
different epitopes had different effects on the distribution of TG2 molecules between 
open and closed conformations, suggesting that binding of some antibodies could have 
implications for TG2 function. We were also able to detect TG2 conformational changes 
induced by the binding of allosteric regulators or cysteine oxidation. The latter was shown 
to prevent Ca2+-induced effects on conformation, suggesting that oxidation inhibits TG2 
activity through prevention of Ca2+ binding. 
Paper III 
Herein, we investigate the ability of antibodies and BCRs to work as substrates to TG2 
and become incorporated into high-molecular weight complexes or crosslinked to gluten 
peptide. We show that IgD is favored over other isoptypes in both types of reaction, 
presumably because of a very long and flexible hinge region that harbors TG2 substrate 
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residues. As TG2-mediated crosslinking of BCRs could be involved in B-cell activation, 
we propose that the unique substrate abilities of IgD result in preferential activation of 
naïve cells and can explain why the anti-TG2 response appears not to be shaped by GC 
reactions. Moreover, mAbs targeting the common VH5-51 epitope was crosslinked more 
efficiently than other mAbs, because TG2 bound through this epitope could act directly 
on its binding partner. This observation provides a possible explanation for the 
preferential activation of B cells using the VH5-51 gene segment. 
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METHODOLOGICAL CONSIDERATIONS
Recombinant protein expression 
TG2 and mAbs used in the experiments were produced recombinantly and purified by 
affinity chromatography. His-tagged TG2 was expressed either in Eschericia coli or in 
Sf9 insect cells. We observed that the protein preparations from the two expression 
systems differed with respect to conformation and antibody binding affinity. In the 
absence of effectors, the insect cell-produced enzyme primarily took the open 
conformation, whereas E. coli-produced TG2 was in the closed conformation. The protein 
purified from insect cells also bound TG2-specific autoantibodies with higher affinity 
than the protein from E. coli. However, both protein preparations could be forced into 
either a closed or an open conformation by adding effector molecules, and they then 
obtained comparable antibody-binding properties. These observations indicate that 
producing the enzyme in a eukaryotic expression system might lead to more optimal 
folding and a protein structure that is recognized better by antibodies. Nevertheless, the 
protein from E. coli could be made into an equally good antigen through the addition of 
effectors. The E. coli expression system, which is much quicker than the Sf9 system, was 
therefore routinely used to generate wild-type and mutant forms of TG2. 
Unlike TG2, antibody molecules contain both disulfide bonds and glycosylations, 
thereby precluding the use of prokaryotic expression systems. The mAbs were instead 
produced by transient co-transfection of H and L chain-encoding DNA into HEK293 cells 
according to an earlier reported protocol [158]. IgG mAbs were subsequently purified 
from the cell supernatants on Protein G, whereas mAbs expressed as other isotypes were 
purified on Protein L, which binds specifically to κ L chains. Hence, purification of non-
IgG antibodies containing λ L chains would not be possible by this approach, but this was 
not a problem in our case, as all mAbs had κ family L chains. 
TG2-antibody binding 
Antibody binding to TG2 was primarily studied by ELISA. Although the assay does not 
give the true affinities of the antibodies, it allows rapid comparison of the binding 
strength of different antibodies to the same antigen, or binding of the same antibody to 
different antigens. In order to properly compare binding strengths, various antibody 
concentrations were used, thereby ensuring sub-saturating levels of antibody in the 
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ELISA. By immobilizing TG2 on microtiter plates, different antibodies can also be added 
in a mixture and their ability to compete with each other for binding assessed. The 
competition ELISA relies on the possibility to distinguish one antibody from the other. 
Competing antibodies were therefore either of different isotype, or one antibody was 
labeled with biotin prior to the experiment. 
Antibody binding to TG2 associated with the ECM could readily be detected by 
immunofluorescence using intestinal tissue sections incubated with the antibodies. The 
approach did not allow visualization of TG2 bound to cell surfaces, though. For this 
purpose we used flow cytometry, as it has earlier been reported that TG2 can be detected 
on the surface of DCs with a TG2-specific mouse mAb [159]. Immature DCs are easily 
obtained from peripheral blood monocytes and are therefore a convenient source of cells 
expressing surface TG2. Whether they are representative of cells that could be interacting 
with TG2-specific B cells in vivo, however, is not clear. In this regard, it would be of 
special interest to know if cells expressing TG2 on their surface are present in the bone 
marrow and can interact with developing B cells. 
Epitope mapping 
Initial grouping of TG2-specific mAbs according to epitope targeting was achieved by 
letting the mAbs compete with each other for binding to TG2 in ELISA. This allowed us 
to confirm the existence of common epitopes but not to determine their location. Since 
the epitopes are conformational, they depend on correct protein folding and cannot be 
mapped by the use of overlapping TG2 peptides. In order to locate the epitopes, we 
therefore had to rely on the introduction of point mutations in TG2. We also assessed 
binding of the mAbs to TG2-fibronectin complexes, in order to see if the epitopes 
targeted by the mAbs overlap with the fibronectin binding site, which is known to be in 
the N-terminal domain of TG2 [160]. 
To get a more detailed picture of the interaction between TG2 and selected mAbs, 
we employed hydrogen/deuterium exchange mass spectrometry, which has previously 
proven to be a powerful tool for the study of protein-protein interactions [161]. By letting 
backbone amide hydrogens exchange with heavy-water deuterium, solvent accessibility 
can be assessed in individual regions of the protein. As exposure to the solvent will 
change in the epitope region upon binding to an antibody, it should be possible to 
pinpoint the binding site. However, we observed that structural changes induced by 
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antibody binding also affects the deuterium uptake in other parts of the protein than the 
epitope. It was therefore necessary to confirm candidate epitopes by site directed 
mutagenesis followed by reactivity assessment of the mutants in ELISA. The 
hydrogen/deuterium exchange method also makes it possible to evaluate the overall 
protein conformation, thereby allowing us to investigate the effect of antibody binding on 
TG2 conformation. In addition, the method was used to investigate binding of the natural 
regulators GTP and Ca2+ as well as the effect of cysteine oxidation on the TG2 structure. 
Ig molecules as TG2 substrates 
TG2 can crosslink various proteins, and the enzyme is also known to crosslink itself 
[162]. In order to distinguish TG2-mediated crosslinking of antibody molecules from 
TG2 auto-crosslinking, proteins were separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) after incubation of active TG2 with 
substrate. TG2-mediated isopeptide bond formation between gluten peptide glutamine 
residues and antibody lysine residues was analyzed using fluorescently labeled gluten 
peptide, leading to the appearance of fluorescent protein bands after SDS-PAGE. By 
measuring the intensity of the fluorescence the amount of antibody-gluten crosslinks 
could be determined under different conditions and with antibodies of various isotypes 
and specificities. TG2-mediated formation of antibody-antibody crosslinks was assessed 
by western blot detection of antibody molecules incorporated into high-molecular weight 
complexes. 
We wished to study the potential role of TG2-mediated isopeptide bond formation 
involving BCR molecules, and it therefore did not suffice to use soluble antibodies only. 
As a model for the reactions taking place on the surface of TG2-specific B cells we 
incubated active TG2, gluten peptide and murine A20 cells retrovirally transduced with 
various BCR constructs as well as HLA-DQ2.5. Ideally, the experiments should involve 
human cells, but the A20 B-cell lymphoma line proved to be a suitable model that was 
easily transduced and expressed appreciable levels of BCR and HLA-DQ2.5 on the 
surface. BCR crosslinking to gluten peptide was evaluated by immunoprecipitation of the 
BCR after incubation of the cells with TG2 and labeled peptide. We also evaluated the 
ability of the transduced cells to present peptides to gluten-specific T cells in the presence 
of TG2 and gluten peptide by employing a previously described T-cell activation assay 
[163]. Although we saw that TG2-mediated crosslinking of BCRs was dependent on 
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isotype and specificity, it was difficult to distinguish individual BCR constructs from 
each other with respect to their ability to mediate peptide uptake and presentation to T 
cells. A likely explanation for this is that free peptide can bind directly to HLA-DQ2.5 on 
the surface of the cells, thereby bypassing receptor-mediated uptake and intracellular 
loading of MHC molecules [164]. Consequently, HLA-DQ2.5-expressing cells can 
present gluten peptides to T cells in vitro, regardless of the specificity of their BCR. This 
is not the case in vivo, probably because B cells will not experience a constant presence 
of concentrated gluten-derived antigen but rather a continuous flow, leading to specific 
activation of those cells that can capture antigen with their BCR. The in vitro cell culture 
system therefore has limitations as a model of T-B cell collaboration in vivo. 
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DISCUSSION
Epitopes targeted by TG2-specific autoantibodies 
There have been several attempts to map the TG2 epitopes that are recognized by 
autoantibodies in celiac disease [157, 165-169]. Most of these studies have focused on the 
ability of serum antibodies to bind truncated versions of TG2 in order to locate antigenic 
regions of the enzyme. Removing parts of TG2, however, might compromise the 
conformation of the remaining polypeptide chain, and loss of antibody reactivity can 
therefore easily be misinterpreted. We and others have previously seen that TG2-specific 
antibodies recognize conformation-dependent epitopes, as denaturing the protein results 
in loss of antibody reactivity [92, 155]. One should therefore be careful when analyzing 
antibody reactivity toward protein that is not intact. In line with this notion, we have 
observed that producing TG2 without the N-terminal β-sandwich domain by recombinant 
expression in E. coli results in low protein yield and lack of enzymatic activity, indicating 
that the protein is misfolded. In contrast, removing the two C-terminal β-barrel domains 
did not have these effects, and the C-terminal deletion thus seems to be conformationally 
tolerable for the remaining polypeptide chain.  
The use of polyclonal antibody sources such as serum makes it challenging to 
localize single antigenic sites, as multiple epitopes are likely to be recognized and 
contribute to the overall binding. Nevertheless, Korponay-Szabo and coworkers recently 
described a single TG2 epitope that was shown to be important for the binding of serum 
antibodies [157]. This epitope could be disrupted by mutating three amino acid residues: 
Arg19, Glu153 and Met659, which are found in close proximity in the closed 
conformation of TG2. We have observed that many TG2-specific mAbs bind 
preferentially to the open TG2 conformation (Paper I), which has also previously been 
shown to be a superior antigen when assessing binding of serum antibodies [170]. This is 
in agreement with the belief that the open conformation is the state the enzyme exists in 
extracellularly. It therefore seems unlikely that the three identified residues should be part 
of the same epitope. Accordingly, Met659, which is close to the C-terminus of the 
protein, was found to play a minor role in the binding of serum antibodies, and the main 
epitope thus appeared to be made up of Arg19 and Glu153 in the intersection between the 
N-terminal domain and the catalytic core domain [157].  
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We have used TG2-specific mAbs instead of polyclonal sera to characterize the 
epitopes targeted by celiac disease autoantibodies (Paper I and II). This allowed us to 
specifically identify single epitopes that could be characterized by mutational analysis of 
the intact protein. By letting individual mAbs compete for binding to TG2, we found that 
few discrete epitopes were recognized. One epitope corresponded to the one previously 
identified [157], and all epitopes seemed to be clustered closely together in the N-terminal 
part of TG2 (Paper I). This was somewhat unexpected and suggests that the 
autoantibodies in celiac disease are the result of highly specific activation of a narrowly 
defined population of TG2-reactive B cells. 
Restricted generation of TG2-reactive plasma cells
TG2-specific, intestinal plasma cells have previously been shown to be restricted in their 
usage of H and L chain variable region gene segments [155, 156]. We have now observed 
that the antibody VH usage correlates with epitope targeting, suggesting that it is a 
limited number of antigenic TG2 epitopes that dictates selection of certain gene segments 
(Paper I). The finding that all identified epitopes are clustered closely together adds 
another level of restriction to the TG2-specific plasma cell population and raises the 
question why only B cells recognizing a small, N-terminal region of the enzyme are 
activated. The explanation for this can either be that B cells recognizing other epitopes 
are negatively selected during their development or that B cells recognizing this particular 
region have an advantage over other TG2-reactive cells during activation.  
Early studies on B-cell tolerance done with transgenic mice suggested that 
membrane-bound self antigens cause clonal deletion of cognate B cells [46, 48], whereas 
soluble self-antigens induce anergy [45]. Later it has been shown that the affinity of an 
autoreactive BCR determines whether the B cell undergoes negative selection, since B 
cells reactive with soluble self-antigen reach the mature, functional stage if they express 
low-affinity BCRs [171, 172]. In agreement with this, it was recently shown that low-
affinity B cells reacting with soluble self-antigen can be identified among normal, 
polyclonal B cells in mice and that these cells are capable of initiating an immune 
response [49]. B cells reactive with membrane-bound self antigen could also be detected, 
but these cells were anergic [49]. It therefore seems as if B cells recognizing membrane-
bound self-antigen are efficiently silenced by deletion or anergy, whereas B cells 
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recognizing soluble self-antigen can escape negative selection, at least if they do not carry 
high-affinity BCRs. 
Since extracellular TG2 can be found both on the surface of cells and attached to 
the ECM, it is possible that B cells react differently with these two forms of the protein. 
While the TG2-specific mAbs recognize ECM-bound TG2, none of eight mAbs 
representing each of the identified epitope groups bound TG2 on the surface of immature 
DCs (Paper I). This suggests that the epitopes targeted by TG2-specific plasma cells are 
hidden on the surface of cells, possibly because they are shielded by TG2-binding 
membrane proteins. Notably, Arg19, which we identified as a key residue for TG2 
binding by one group of mAbs (Paper II), has also been implicated in the interaction 
between TG2 and heparan sulfate proteoglycans on the surface of cells [173]. It is 
plausible that B cells reacting with parts of TG2 not shielded on the surface of cells will 
undergo negative selection and are therefore not represented in the plasma cell 
population. Although ECM-bound TG2 is not soluble in the sense that it can diffuse 
freely, it is likely that it will not have the same impact on BCR signaling as membrane-
bound TG2. Hence, ECM-bound TG2 should not induce the same level of BCR clustering 
as membrane-bound TG2, thereby allowing B cells that only react with the former variant 
to escape negative selection.
As mentioned above, it is also possible that the restricted targeting of TG2 epitopes 
by autoantibodies in celiac disease reflects an advantage of a subset of TG2-reactive B 
cells during activation rather than negative selection of all other TG2-reactive cells. 
Hence, the preferred activation of cells recognizing epitopes clustered in the N-terminal 
domain might be explained by a need for correct orientation of the BCR-bound enzyme. 
Following this line of thought, the ability of BCR-bound TG2 to catalyze crosslinking 
reactions on the cell surface could be instrumental in B-cell activation (Paper III). Our 
previously reported finding that TG2-specific mAbs do not inhibit the activity of the 
enzyme speaks in favor of such a model [155]. 
Activation mechanism for TG2-reactive B cells 
The connection between celiac disease and the production of TG2-specific autoantibodies 
has previously been explained in a model which suggests that TG2-reactive B cells can 
receive activation help from gluten-reactive CD4+ T cells after uptake of TG2-gluten 
complexes and subsequent presentation of gluten-derived peptides on MHC class II 
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molecules [174]. The proposed collaboration between T and B cells explains the strict 
gluten dependence of TG2-specific serum antibodies [92] and the observation that only 
individuals carrying the disease-associated HLA genes produce the autoantibodies [175]. 
Moreover, the model is supported by the finding that TG2 can crosslink itself to gluten-
derived peptides in vitro, thereby creating stable hapten-carrier like complexes [91, 162]. 
We recently showed that such complexes can be taken up by transduced A20 cells 
expressing a TG2-specific BCR and HLA-DQ2.5 followed by presentation of peptide to 
gluten-reactive T cells [155]. It is possible that TG2-gluten complexes can be made up of 
larger, crosslinked aggregates containing multiple TG2 molecules and gluten-derived 
peptides linked together by isopeptide bonds. This type of complexes would be able to 
induce BCR clustering, thereby giving the initial signal for B-cell activation, and could 
serve as antigen for both TG2- and gluten-specific B cells. 
Given the proposed T-cell dependence of TG2-specific antibodies and the chronic 
exposure to both TG2 and gluten in untreated celiac disease, one would expect the anti-
TG2 response to display signs of extensive GC activity. However, TG2-specific plasma 
cells were shown to have few somatic mutations, and TG2-specific memory B cells were 
not readily detectable in peripheral blood of celiac disease patients [155], indicating that 
GC reactions are not shaping the anti-TG2 response to a large degree. Lack of GC activity 
is also supported by the observation that TG2-specific serum antibodies disappear from 
the circulation within months after patients commence a gluten-free diet [92, 176], 
suggesting that long-lived, bone marrow-residing plasma cells are not generated. 
Nevertheless, upon reverting somatic mutations for a selection of TG2-specific mAbs in 
order to obtain their predicted germline configuration, all but one mAb displayed reduced 
affinity, suggesting that the mutations which occur are not random but that TG2-specific 
B cells undergo T cell-dependent selection [155]. Collectively, these observations 
indicate that gluten-specific T cells are likely to drive the activation of TG2-specific B 
cells, but for some reason GC reactions appear to be absent or very limited.  
Recently, it was proposed that pemphigus vulgaris autoantibodies targeting the 
protein desmoglein 3 are derived from B cells that originally reacted with other, possibly 
microbial, antigens but acquired autoreactivity through SHM [177]. This does not seem to 
be the case for the anti-TG2 response in celiac disease, as TG2-reactive mAbs still 
recognized the autoantigen when reverted to their germline configuration [155]. Hence, 
the induction of the response should involve TG2-reactive naïve B cells. 
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In the models we now propose for activation of TG2-reactive B cells, the BCR is 
directly involved in TG2-mediated crosslinking, either to gluten-derived peptides or to 
neighboring BCR molecules (Paper III). BCR crosslinking to gluten peptides would lead 
to receptor-mediated uptake of gluten peptides by cells binding TG2 and thus allow 
interactions with gluten-reactive CD4+ T cells. BCR-BCR crosslinking, on the other hand, 
would lead to intracellular signaling and thereby provide the cue for migration of B cells 
to the border between the follicle and the T-cell zone as well as BCR stimulation during T 
cell-mediated activation and selection. It is possible that both types of TG2-mediated 
BCR crosslinking are involved in B-cell activation. Interestingly, among the various 
human isotypes IgD was the favored substrate in both reaction types, suggesting that the 
reactions can occur on naïve B cells expressing IgD on their surface but not on cells that 
have undergone CSR. Since B cells lose expression of IgD when they enter the GC [178], 
the models suggest that B-cell activation and interaction with gluten-reactive T cells will 
not take place in this compartment. The ability of the BCR to work as a substrate for TG2 
therefore provides a possible explanation for the features of the anti-TG2 response 
speaking against GC activity. Moreover, the proposed models imply that correct 
orientation of BCR-bound TG2 is important for B-cell activation, since the enzyme must 
be able to catalyze crosslinking on the cell surface. Hence, it is possible that the need for 
enzyme activity contributes to the restricted targeting of epitopes by TG2-specific plasma 
cells.
We observed that TG2-mediated crosslinking between BCR and gluten peptide is 
most efficient if the BCR reacts with the epitope recognized by most mAbs using the 
VH5-51 gene segment, presumably because binding through this epitope allows the 
enzyme to act on the same BCR molecule to which it is bound (Paper III). This 
phenomenon might explain why the VH5-51 segment is preferred among TG2-reactive 
plasma cells [155, 156]. We have also shown that TG2 can cleave crosslinks between IgD 
and gluten peptide leading to peptide deamidation. If this happens after endocytosis of a 
crosslinked BCR complex, the model can explain how gluten peptide is taken up, released 
and deamidated prior to presentation to gluten-reactive T cells. Deamidation is thereby 
directly incorporated into the antigen uptake process, making the B cell an attractive 
candidate as the primary APC that presents peptides to gluten-reactive T cells. The 
coupling between TG2 activity and antigen presentation also fits with the finding that the 
best TG2 substrates in a proteolytic digest of gluten are the peptides that correspond to 
major T-cell epitopes in celiac disease [179].
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A central role of the B cell as the APC that initiates T-cell activation has recently 
been suggested for nucleic acid-reactive B cells in systemic lupus erythematosus [180]. A 
similar role of TG2-reactive B cells in celiac disease might explain why gluten-reactive T 
cells target deamidated rather than native gluten epitopes [75, 76]. According to the 
models we propose, TG2-reactive B cells present gluten-derived peptides through a 
mechanism that couples uptake directly to deamidation. This will not be the case for DCs. 
At the same time, bypassing DCs during T-cell priming could also explain how oral 
tolerance to gluten is broken in celiac disease. 
Location and origin of TG2-specific antibody-secreting cells 
TG2-specific antibodies in serum are thought to derive from gut plasma cells, since TG2-
reactive antibody sequences could be obtained from intestinal lymphocytes but not from 
peripheral blood lymphocytes of celiac disease patients [156]. Nevertheless, while TG2-
specific IgG is readily detectable in serum, virtually no secretion of TG2-reactive IgG 
could be measured in intestinal biopsies [155]. This suggests that the IgG antibodies in 
serum are produced elsewhere, most likely in secondary lymphoid tissues or in the bone 
marrow. Although TG2-reactive IgA is secreted from intestinal biopsies of celiac disease 
patients, it is possible that anti-TG2 IgA in serum is produced in a different place, as most 
of total IgA produced in the gut should be secreted into the intestinal lumen, while serum 
IgA appears to be produced elsewhere [30, 181]. The TG2-specific mAbs we have cloned 
from IgA-producing plasma cells therefore might not be representative of the antibodies 
found in serum of celiac disease patients. Nevertheless, polyclonal antibodies in both 
serum and biopsy secretions seem to target the same epitopes as the TG2-specific mAbs 
(Paper I). It is therefore reasonable to believe that the antibodies in serum are generated in 
the same way as TG2-specific antibodies produced in the gut. 
TG2-specific B cells should, as other B cells, become activated after encountering 
their cognate antigen in secondary lymphoid tissue. According to the models we have 
proposed, the site for B-cell activation should be accessible to gluten peptides, and active 
TG2 should be available. After a gluten-containing meal, peptides derived from the 
enzymatic digestion of gluten will most likely drain passively to the subcapsular sinuses 
of mesenteric lymph nodes through afferent lymphatics. Due to their small size they will 
be able to enter the follicles through a system of conduits and thereby get direct access to 
B cells [182, 183].
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When it comes to TG2, the enzyme has earlier been shown to be expressed in 
lymph nodes [131], and it should therefore be available for binding to B cells. TG2 
activity has also been demonstrated in lysates of peripheral blood lymphocytes [184], 
suggesting that B cells might even be able to provide the autoantigen themselves. 
Although TG2 is present in lymph nodes, it is not given that the enzyme exists in a 
catalytically active state as required by the models. Despite its abundance, extracellular 
TG2 in mouse small intestine was found to be catalytically inactive during normal 
conditions in vivo [141, 142], presumably as a result of oxidation of key cysteine residues 
[143]. However, newly secreted TG2 might be active for a short period of time before the 
enzyme is inactivated by oxidation, and this could be sufficient for B-cell activation. It is 
also possible that large amounts of active TG2 are released from dying cells, which will 
be abundant in GCs, thereby contributing to increased TG2 activity in lymph nodes with 
ongoing GC reactions. Alternatively, the TG2 activity required for B-cell activation could 
be the result of reduction of oxidized, extracellular TG2. Notably, TG2 activity can be 
induced in tissue sections or cell cultures through administration of a reducing agent or 
the redox protein thioredoxin, suggesting that TG2 activity can be turned on by a local 
change in the redox environment [144]. Interestingly, a reducing microenvironment is 
thought to be important for lymphocyte activation [185-187], and it has been 
demonstrated that the secretion of thioredoxin by DCs upon interaction with T cells can 
contribute to the generation of optimal redox conditions during an immune response 
[188]. Thus, it is possible that immune responses alter the extracellular redox 
environment in a way that contributes to local activation of TG2. In this respect, transient 
activation of TG2 by a more reducing microenvironment could be the event that triggers 
activation of TG2-reactive B cells and thereby initiates celiac disease development. 
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CONCLUDING REMARKS AND FUTURE PERSPECTIVES
The immunological mechanisms responsible for the production of autoantibodies are in 
most cases poorly understood. In this sense, the anti-TG2 response in celiac disease is 
special, as there is a known environmental trigger, gluten, and we can explain the basis 
for the HLA association through presentation of gluten-derived peptides by APCs. The 
presence of gluten-reactive CD4+ T cells in the celiac lesion is well established, and it is 
conceivable that these cells can provide activation help to TG2-reactive B cells. Where 
and how this T-B cell collaboration takes place, however, is not known.
By using a panel of TG2-specific mAbs generated from plasma cells in intestinal 
biopsies of celiac disease patients, we have shown that the autoantibodies target few 
epitopes that are clustered together in a small region in the N-terminal part of the enzyme. 
We propose that this clustering can be explained by negative selection of B cells targeting 
other epitopes or by preferred activation of B cells reacting with this particular part of 
TG2. In order to distinguish between the two possibilities it will be informative to look 
into the naïve repertoire of TG2-specific B cells. If these cells can be identified and 
isolated from peripheral blood, it should be possible to compare naïve cells and plasma 
cells with respect to gene segment usage and epitope targeting. Hence, characterization of 
naïve TG2-specific B cells should allow us to answer whether a subset of TG2-reactive B 
cells undergo negative selection and thereby indirectly inflict restrictions upon the TG2-
targeting plasma cells.  
As an alternative or complementing factor to negative selection, the plasma cell 
repertoire might be shaped by restricted activation of B cells, i.e. only cells binding TG2 
in a specific way will become activated. We have proposed that the transglutaminase 
activity of the enzyme is directly involved in B-cell activation through generation of 
BCR-BCR or BCR-gluten crosslinks. Hence, only B cells that bind TG2 in an orientation 
that allows surface crosslinking would become activated. This model potentially explains 
the VH5-51 gene segment preference among TG2-specific plasma cells, since antibodies 
binding the common VH5-51 epitope were crosslinked more efficiently than other 
antibodies. In addition, we saw that antibodies and BCRs of the IgD isotype are superior 
as TG2 substrates compared to other isotypes. This phenomenon might explain the 
apparent lack of GC activity in the generation of the anti-TG2 response.  
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To further study the role of TG2-reactive B cells in celiac disease we are now in the 
process of generating a knock-in mouse carrying H and L chain variable regions from a 
TG2-specific human mAb. This mouse model should make it possible to study the 
collaboration between TG2-reactive B cells and gluten-reactive T cells in vivo and allow 
us to address whether the anti-TG2 response is generated extrafollicularly or in GCs. 
Hopefully, this will help us elucidate the mechanisms underlying the production of 
autoantibodies against TG2 in celiac disease and provide us with details explaining how 
an autoimmune response can be initiated. 
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